<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CALDOLOR- ibuprofen injection </strong><br>Cumberland Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Caldolor safely and effectively.  See full prescribing information for Caldolor.  <br>CALDOLOR (ibuprofen) Injection, for intravenous use<br>Initial U.S. Approval: 1974
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold Underline">Cardiovascular Risk</span> </p>
<ul class="Disc">
<li><span class="Bold">Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Risk may increase with duration of use. (<a href="#s15">5.1</a>)</span></li>
<li><span class="Bold">Caldolor is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#s13">4.3</a>, <a href="#s15">5.1</a>)</span></li>
</ul>
<p class="Highlighta"><span class="Bold Underline">Gastrointestinal Risk</span> </p>
<ul class="Disc"><li><span class="Bold">NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. Events can occur at any time without warning symptoms. Elderly patients are at greater risk. (<a href="#s16">5.2</a>)</span></li></ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold Underline">Cardiovascular Risk</span> </p>
<ul class="Disc">
<li><span class="Bold">Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Risk may increase with duration of use. (<a href="#s15">5.1</a>)</span></li>
<li><span class="Bold">Caldolor is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#s13">4.3</a>, <a href="#s15">5.1</a>)</span></li>
</ul>
<p class="Highlighta"><span class="Bold Underline">Gastrointestinal Risk</span> </p>
<ul class="Disc"><li><span class="Bold">NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. Events can occur at any time without warning symptoms. Elderly patients are at greater risk. (<a href="#s16">5.2</a>)</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Caldolor is an NSAID indicated in adults for the:
 </p>
<ul class="Disc">
<li>Management of mild to moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (<a href="#s3">1.1</a>)
</li>
<li>Management of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as an adjunct to opioid analgesics (<a href="#s3">1.1</a>)
</li>
<li>Reduction of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (<a href="#s4">1.2</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>: 400 mg to 800 mg intravenously over 30 minutes every 6 hours as necessary. (<a href="#s6">2.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>: 400 mg intravenously over 30 minutes, followed by 400 mg every 4 to 6 hours or 100-200 mg every 4 hours as necessary. (<a href="#s7">2.2</a>)
</li>
<li>Patients must be well hydrated before Caldolor administration.
</li>
<li>Caldolor must be diluted before administration. (<a href="#s8">2.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Vials: 800 mg/8 mL (<a href="#s9">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ibuprofen or other NSAIDs (<a href="#s11">4.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs (<a href="#s12">4.2</a>)
</li>
<li>Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery (<a href="#s13">4.3</a>, <a href="#s15">5.1</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious and potentially fatal CV thrombotic events: Use lowest effective dose of Caldolor for shortest possible duration.
(<a href="#s15">5.1</a>)
</li>
<li>Serious and potentially fatal GI reactions: Use lowest effective dose of Caldolor for shortest possible duration. Use with caution in patients with prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#s16">5.2</a>)
</li>
<li>Hepatic effects: Range from transaminase elevations to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.  Discontinue Caldolor immediately if abnormal liver tests persist or worsen. (<a href="#s17">5.3</a>, <a href="#s29">5.15</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: Can occur with NSAID treatment. Monitor blood pressure closely during treatment with Caldolor. (<a href="#s18">5.4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> can occur with NSAID treatment. Use Caldolor with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#s19">5.5</a>)
</li>
<li>Renal effects: Long-term administration of NSAIDs can result in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Use Caldolor with caution in patients at risk (e.g., the elderly, those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver impairment, and those taking diuretics or ACE inhibitors). (<a href="#s20">5.6</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span>: May occur in patients with the aspirin triad or in patients without prior exposure to Caldolor. Discontinue Caldolor immediately if an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs. (<a href="#s21">5.7</a>, <a href="#s26">5.12</a>)
</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>: Include <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, which can be fatal.  Discontinue Caldolor if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> occur. (<a href="#s22">5.8</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (&gt;5%). (<a href="#s31">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Cumberland Pharmaceuticals Inc. at 1-877-484-2700 or FDA at 1-800-FDA-1088 or
</span><span class="Bold Italics">www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>ACE inhibitors: NSAIDs may diminish the antihypertensive effect of ACE inhibitors. (<a href="#s37">7.3</a>)
</li>
<li>Aspirin: Concomitant administration of ibuprofen and aspirin is not generally recommended because of the potential for increased adverse effects. (<a href="#s35">7.1</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Avoid use after 30 weeks gestation because premature closure of the ductus arteriosus in the fetus may occur. (<a href="#s43">8.1</a>)
</li>
<li>Nursing Mothers: Use with caution as it is not known if ibuprofen is excreted in human milk. (<a href="#s46">8.3</a>)
</li>
<li>Pediatric Use: Safety and effectiveness not established in patients less than 17 years of age. (<a href="#s47">8.4</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>)
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Antipyretic (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>)
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>)
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Antipyretic (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>)
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3   Preparation and Administration
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h2><a href="#section-4.2" class="toc">4.2    <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>
</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Coronary Artery Bypass Graft (CABG)
</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Cardiovascular Thrombotic Events
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatic Effects
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Renal Effects
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Pregnancy
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Masking <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Hematological Effects
</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Ophthalmological Effects
</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span>
</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Monitoring
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Aspirin
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Anticoagulants
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 ACE Inhibitors
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Diuretics
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Lithium
</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Methotrexate
</a></h2>
<h2><a href="#section-7.7" class="toc">7.7  H-2 Antagonists
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc"> 12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-12.1" class="toc">14.1  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>)
</a></h2>
<h2><a href="#section-12.2" class="toc">14.2  Antipyretic (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>)
</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-14.1" class="toc">17.1 Cardiovascular Effects
</a></h2>
<h2><a href="#section-14.2" class="toc">17.2 Gastrointestinal Effects
</a></h2>
<h2><a href="#section-14.3" class="toc">17.3 Hepatotoxicity
</a></h2>
<h2><a href="#section-14.4" class="toc">17.4 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>
</a></h2>
<h2><a href="#section-14.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</a></h2>
<h2><a href="#section-14.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</a></h2>
<h2><a href="#section-14.7" class="toc">17.7 Effects During Pregnancy
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
</h1>
<p class="First"><span class="Bold Underline">Cardiovascular Risk</span></p>
<ul class="Disc">
<li>
<span class="Bold">Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk
</span><span class="Bold Italics">[see Warnings and Precautions (</span><span class="Bold Italics"><a href="#s15">5.1</a>)</span><span class="Bold Italics">]</span>.
</li>
<li>
<span class="Bold">Caldolor is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery
</span><span class="Bold Italics">[see Contraindications (<a href="#s13">4.3</a>) and Warnings and Precautions (<a href="#s15">5.1</a>)].</span>
</li>
</ul>
<p><span class="Bold Underline">Gastrointestinal Risk</span></p>
<ul class="Disc"><li>
<span class="Bold">NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events
</span><span class="Bold Italics">[see Warnings and Precautions (</span><span class="Bold Italics"><a href="#s16">5.2</a>)]</span>.
</li></ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>)
</h2>
<p class="First">Caldolor is indicated in adults for the management of mild to moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and the management of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as an adjunct to opioid analgesics.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Antipyretic (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>)
</h2>
<p class="First">Caldolor is indicated for the reduction of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in adults.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s5"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals <span class="Italics">[see Warnings and Precautions (<a href="#s14">5</a>)]</span>. After observing the response to initial therapy with Caldolor, the dose and frequency should be adjusted to suit an individual patient's needs. Do not exceed 3200 mg total daily dose.
</p>
<p>To reduce the risk of renal adverse reactions, patients must be well hydrated prior to administration of Caldolor.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>)
</h2>
<p class="First">Administer 400 mg to 800 mg intravenously every 6 hours as necessary. Infusion time must be no less than 30 minutes.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Antipyretic (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>)
</h2>
<p class="First">Administer 400 mg intravenously, followed by 400 mg every 4 to 6 hours or 100-200 mg every 4 hours as necessary.  Infusion time must be no less than 30 minutes.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.3"></a><p></p>
<h2>2.3   Preparation and Administration
</h2>
<p class="First">Caldolor <span class="Bold">must be diluted</span> prior to intravenous infusion. Dilute to a final concentration of 4 mg/mL or less.  Appropriate diluents include 0.9% Sodium Chloride Injection USP (normal saline), 5% Dextrose Injection USP (D5W), or Lactated Ringers Solution.
</p>
<ul class="Disc">
<li>800 mg dose: Dilute 8 mL of Caldolor in no less than 200 mL of diluent.
</li>
<li>400 mg dose: Dilute 4 mL of Caldolor in no less than 100 mL of diluent.
</li>
</ul>
<p>Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. If visibly opaque particles, discoloration or other foreign particulates are observed, the solution should not be used.
</p>
<p>Diluted solutions are stable for up to 24 hours at ambient temperature (approximately 20 to 25° C) and room lighting.
</p>
<p>Infusion time must be no less than 30 minutes.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Caldolor is available as an 800 mg/8 mL single-dose vial (100 mg/mL).
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">Caldolor is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>) to ibuprofen <span class="Italics">[see Warnings and Precautions (<a href="#s21">5.7</a>, <a href="#s22">5.8</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-4.2"></a><p></p>
<h2>4.2    <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>
</h2>
<p class="First">Caldolor is contraindicated in patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal anaphylactic-like reactions to NSAIDs have been reported in such patients <span class="Italics">[see Warnings and Precautions (<a href="#s21">5.7</a>, <a href="#s26">5.12</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Coronary Artery Bypass Graft (CABG)
</h2>
<p class="First">Caldolor is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s14"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Cardiovascular Thrombotic Events
</h2>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.
</p>
<p> Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="Italics">[see Contraindications (<a href="#s13">4.3</a>)]</span>.
</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious gastrointestinal (GI) events <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a></span>)<span class="Italics">]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation
</h2>
<p class="First">NSAIDs, including ibuprofen, can cause serious GI adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months and in about 2-4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.
</p>
<p>Prescribe NSAIDs, including Caldolor, with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to treated patients with neither of these risk factors. Other factors that increase the risk of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most reports of spontaneous fatal GI events are in elderly or debilitated patients, and therefore special care should be taken in treating this population.
</p>
<p>To minimize the potential risk for an adverse GI event in patients treated with an NSAID, use the lowest effective dose for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatic Effects
</h2>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including ibuprofen. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions have been reported, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some with fatal outcomes. A patient with symptoms and/or signs suggesting liver dysfunction, or with abnormal liver test values, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with ibuprofen. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), ibuprofen should be discontinued.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</h2>
<p class="First"> NSAIDs, including ibuprofen, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Use NSAIDs, including ibuprofen, with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure closely during the initiation of NSAID treatment and throughout the course of therapy.
</p>
<p>Patients taking ACE inhibitors, thiazides, or loop diuretics may have impaired response to these therapies when taking NSAIDs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.5"></a><p></p>
<h2>5.5  <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. Use Caldolor with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Renal Effects
</h2>
<p class="First">Use caution when initiating treatment with Caldolor in patients with considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.
</p>
<p>Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics or ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.
</p>
<p>No information is available from controlled clinical studies regarding the use of Caldolor in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.   If Caldolor therapy must be initiated in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, closely monitor the patient's renal function.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to ibuprofen. Caldolor is contraindicated in patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs <span class="Italics">[see Contraindications (<a href="#s12">4.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>
</h2>
<p class="First"> NSAIDs, including ibuprofen, can cause serious skin adverse reactions such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin manifestations, and to discontinue Caldolor at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Pregnancy
</h2>
<p class="First">Starting at 30 weeks gestation, Caldolor, and other NSAIDs, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur <span class="Italics">[see Use in Specific Populations (<a href="#s43">8.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Masking <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</h2>
<p class="First">The pharmacological activity of ibuprofen in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Hematological Effects
</h2>
<p class="First">Caldolor must be diluted prior to use.  Infusion of the drug product without dilution can cause <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> <span class="Italics">[see Dosage and Administration (<a href="#s8">2.3</a>)]</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> may occur in patients receiving NSAIDs, including ibuprofen. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect on erythropoiesis. In patients on long-term treatment with NSAIDs, including ibuprofen, check hemoglobin or hematocrit if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or blood loss.
</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effects on platelet function are less severe quantitatively, of shorter duration, and reversible. Carefully monitor patients who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Since cross-reactivity between aspirin and NSAIDs has been reported in such aspirin-sensitive patients, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, Caldolor is contraindicated in patients with this form of aspirin sensitivity and should be used with caution in all patients with pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Ophthalmological Effects
</h2>
<p class="First">Blurred or diminished vision, scotomata, and changes in color vision have been reported with oral ibuprofen. Discontinue ibuprofen if a patient develops such complaints, and refer the patient for an ophthalmologic examination that includes central visual fields and color vision testing.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> has been observed in patients on oral ibuprofen therapy. Although it is probably more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and related connective tissue diseases, it has been reported in patients who do not have underlying chronic disease. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> develop in a patient on ibuprofen, give consideration to whether or not the signs or symptoms are related to ibuprofen therapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Monitoring
</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.
</p>
<p>Patients on long-term treatment with NSAIDs should have CBC and chemistry profiles checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>), or abnormal liver tests persist or worsen, discontinue Caldolor.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s30"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:
</p>
<ul class="Disc">
<li>Cardiovascular thrombotic events <span class="Italics">[see <a href="#s1">Boxed Warning</a> and Warnings and Precautions (<a href="#s15">5.1</a>)]</span>
</li>
<li>Gastrointestinal effects <span class="Italics">[see <a href="#s1">Boxed Warning</a> and Warnings and Precautions (<a href="#s16">5.2</a>)]</span>
</li>
<li>Hepatic effects <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.4</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.5</a>)]</span>
</li>
<li>Renal effects <span class="Italics">[see Warnings and Precautions (<a href="#s20">5.6</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> <span class="Italics">[see Warnings and Precautions (<a href="#s21">5.7</a>)]</span>
</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> <span class="Italics">[see Warnings and Precautions (<a href="#s22">5.8</a>)]</span>
</li>
</ul>
<p>The most common adverse reactions reported in clinical studies are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.
</p>
<p>The most common reason for discontinuation due to adverse events in controlled trials of Caldolor is <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (&lt;1%).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared directly to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>During clinical development, 560 patients were exposed to Caldolor, 438 in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and 122 with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. In the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> studies, Caldolor was started intra-operatively and administered at a dose of 400 mg or 800 mg every six hours for up to three days. In the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> studies, Caldolor was administered at doses of 100 mg, 200 mg, or 400 mg every four or six hours for up to 3 days.
</p>
<p>The most frequent type of adverse reaction occurring with oral ibuprofen is gastrointestinal.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Studies</span></p>
<p>The incidence rates of adverse reactions listed in the following table were derived from multi-center, controlled clinical studies in post-operative patients comparing Caldolor to placebo in patients also receiving morphine as needed for post-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Post-operative  Patients with Adverse Reactions Observed in ≥ 3% of Patients in any Caldolor Treatment Group in  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Studies<span class="Sup">*</span></span></caption>
<col align="left" width="37.284%">
<col align="left" width="20.905%">
<col align="left" width="20.905%">
<col align="left" width="20.905%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">* All patients received concomitant morphine during these studies.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"><span class="Bold">Event</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><span class="Bold">Caldolor</span></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Placebo<br>(N=287)</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">400 mg<br>(N=134)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">800 mg<br>(N=304)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Any Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">118 (88%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">260 (86%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">258 (90%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">77 (57%)
</td>
<td class="Botrule Rrule" align="center" valign="top">161 (53%)
</td>
<td class="Botrule Rrule" align="center" valign="top">179 (62%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">30 (22%)
</td>
<td class="Botrule Rrule" align="center" valign="top">46 (15%)
</td>
<td class="Botrule Rrule" align="center" valign="top">50 (17%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">49 (16%)
</td>
<td class="Botrule Rrule" align="center" valign="top">44 (15%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12 (9%)
</td>
<td class="Botrule Rrule" align="center" valign="top">35 (12%)
</td>
<td class="Botrule Rrule" align="center" valign="top">31 (11%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">13 (4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">16 (6%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8 (6%)
</td>
<td class="Botrule Rrule" align="center" valign="top">13 (4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">5 (2%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (&lt;1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">9 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (1%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7 (5%)
</td>
<td class="Botrule Rrule" align="center" valign="top">10 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">10 (3%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5 (4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">7 (2%)
</td>
<td class="Botrule Rrule" align="center" valign="top">6 (2%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Decreased hemoglobin</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">6 (2%)
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (1%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6 (4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (&lt;1%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4343234" conceptname="Wound hemorrhage">Wound hemorrhage</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (1%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (&lt;1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (&lt;1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (&lt;1%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5 (4%)
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (&lt;1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">8 (3%)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> Studies</span></p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> studies were conducted in febrile hospitalized patients with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> and febrile hospitalized patients with varying causes of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. In hospitalized febrile patients with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, the adverse reactions observed in at least two Caldolor-treated patients included <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>.
</p>
<p>In hospitalized febrile patients (all causes), adverse reactions observed in more than two patients in any given treatment group are presented in the table below.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Patients with Adverse Reactions Observed in ≥ 3% of Patients in any Caldolor Treatment Group in All-Cause <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> Study
</span></caption>
<col align="left" width="35.766%">
<col align="left" width="14.274%">
<col align="left" width="16.653%">
<col align="left" width="16.653%">
<col align="left" width="16.653%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left" rowspan="2" valign="bottom"><span class="Bold">Event</span></th>
<th class="Botrule Rrule" align="center" colspan="3" valign="bottom"><span class="Bold">Caldolor</span></th>
<th class="Botrule Rrule" align="center" rowspan="2" valign="bottom">
<span class="Bold">Placebo</span><br><span class="Bold">N=28</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">100 mg</span><br><span class="Bold">N=30</span>
</th>
<th class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">200 mg</span><br><span class="Bold">N=30</span>
</th>
<th class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">400 mg</span><br><span class="Bold">N=31</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Any Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">27 (87%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">25 (83%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">23 (74%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">25 (89%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5 (17%)
</td>
<td class="Botrule Rrule" align="center" valign="top">6 (20%)
</td>
<td class="Botrule Rrule" align="center" valign="top">11 (36%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (14%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7 (23%)
</td>
<td class="Botrule Rrule" align="center" valign="top">7 (23%)
</td>
<td class="Botrule Rrule" align="center" valign="top">8 (26%)
</td>
<td class="Botrule Rrule" align="center" valign="top">7 (25%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (13%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (13%)
</td>
<td class="Botrule Rrule" align="center" valign="top">6 (19%)
</td>
<td class="Botrule Rrule" align="center" valign="top">5 (18%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">Hypoproteinemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (13%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (13%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    Blood urea increased
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Hypernatremia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (4%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (4%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="257315" conceptname="Bacterial pneumonia">Pneumonia bacterial</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    Blood LDH increased
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (4%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (13%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s34"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Aspirin
</h2>
<p class="First">When ibuprofen is administered with aspirin, ibuprofen's protein binding is reduced, although the clearance of free ibuprofen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of Caldolor and aspirin is not generally recommended because of the potential for increased adverse effects.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Anticoagulants
</h2>
<p class="First">The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that the users of both drugs together have a higher risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> than users of either drug alone <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-7.3"></a><p></p>
<h2>7.3 ACE Inhibitors
</h2>
<p class="First">NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Diuretics
</h2>
<p class="First">Clinical studies and postmarketing observations have shown that ibuprofen can reduce the natriuretic effects of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, observe patients closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, as well as to assure diuretic efficacy <span class="Italics">[see Warnings and Precautions (<a href="#s20">5.6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Lithium
</h2>
<p class="First">NSAIDs have produced elevations of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance of lithium decreased by 20%. This effect has been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, observe patients carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Methotrexate
</h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This indicates that NSAIDs may enhance the toxicity of methotrexate. Use caution when NSAIDs are administered concomitantly with methotrexate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-7.7"></a><p></p>
<h2>7.7  H-2 Antagonists
</h2>
<p class="First">In studies of human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s42"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s43"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s44"></a><a name="section-8.1.1"></a><p></p>
<p class="First">Teratogenic effects - Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation.
</p>
<p>Starting at 30 weeks gestation, Caldolor, and other NSAIDs, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur.  Caldolor can cause fetal harm when administered to a pregnant woman starting at 30 weeks gestation.
</p>
<p>There are no adequate, well-controlled studies in pregnant women. Prior to 30 weeks gestation, Caldolor should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<p>Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s45"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">The effects of Caldolor on labor and delivery in pregnant women are unknown.  In rat studies, maternal exposure to NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, increased the incidence of dystocia and delayed parturition, and decreased pup survival.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s46"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Caldolor, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s47"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First"> Safety and effectiveness of Caldolor for management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and reduction of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> has not been established in pediatric patients below the age of 17 years.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s48"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First"> Clinical studies of Caldolor did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.  Elderly patients are at increased risk for serious GI adverse events.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s49"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">The following signs and symptoms have occurred in individuals following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of oral ibuprofen:  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. There are no specific measures to treat acute overdosage with Caldolor.  There is no known antidote to ibuprofen. In case of an overdosage, discontinue Caldolor therapy and consider contacting a regional poison control center at 1-800-222-1222.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s50"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">Caldolor contains the active ingredient ibuprofen, which is (±)-2-(<span class="Italics">p</span>-isobutylphenyl) propionic acid. Ibuprofen is a white powder with a melting point of 74-77°C.  It has a molecular weight of 206.28.  It is very slightly soluble in water (&lt;1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. The structural formula of ibuprofen is represented below:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1eaa7790-f1a1-4f51-b10a-cbbaf033f684&amp;name=cal05-0000-01.jpg">
</div>
<p>Each 1 mL of solution contains 100 mg of ibuprofen in Water for Injection, USP.  The product also contains 78 mg/mL arginine at a molar ratio of 0.92:1 arginine:ibuprofen.  The solution pH is about 7.4.
</p>
<p>Caldolor is sterile and is intended for intravenous administration only.
</p>
<p>.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s51"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s52"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action
</h2>
<p class="First">Ibuprofen's mechanism of action, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.  Caldolor possesses anti-inflammatory, analgesic, and antipyretic activity.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s53"></a><a name="section-11.2"></a><p></p>
<h2> 12.3 Pharmacokinetics
</h2>
<p class="First">Ibuprofen is a racemic mixture of [-]R- and [+]S-isomers. In vivo and in vitro studies indicate that the [+]S-isomer is responsible for clinical activity. The [-]R-form, while thought to be pharmacologically inactive, is slowly and incompletely (~60%) interconverted into the active [+]S species in adults. The [-]R-isomer serves as a circulating reservoir to maintain levels of active drug. The pharmacokinetic parameters of Caldolor determined in a study with volunteers are presented below.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Pharmacokinetic Parameters of Intravenous Ibuprofen
</span></caption>
<col align="left" width="35.700%">
<col align="left" width="30.967%">
<col align="left" width="33.333%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">AUC = Area-under-the-curve
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">Cmax = Peak plasma concentration
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">CV = Coefficient of Variation
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">KEL = First-order elimination rate constant
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">T<span class="Sub">1/2</span> = Elimination half-life
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">* = 60 minute infusion time
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">400 mg* Caldolor<br>Mean (CV%)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">800 mg* Caldolor<br>Mean (CV%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Number of Patients
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">AUC (mcg·h/mL)
</td>
<td class="Botrule Rrule" align="center" valign="top">109.3 (26.4)
</td>
<td class="Botrule Rrule" align="center" valign="top">192.8 (18.5)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">max</span> (mcg/mL)
</td>
<td class="Botrule Rrule" align="center" valign="top">39.2 (15.5)
</td>
<td class="Botrule Rrule" align="center" valign="top">72.6 (13.2)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">KEL (1/h)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.32 (17.9)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.29 (12.8)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">T<span class="Sub">1/2</span> (h)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.22 (20.1)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.44 (12.9)
</td>
</tr>
</tbody>
</table>
<p>Ibuprofen, like most NSAIDs, is highly protein bound (&gt;99% bound at 20 mcg/mL). Protein binding is saturable, and at concentrations &gt;20 mcg/mL binding is nonlinear. Based on oral dosing data, there is an age- or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>-related change in volume of distribution for ibuprofen.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s54"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-12.1"></a><p></p>
<h2>14.1  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>)
</h2>
<p class="First"> The effect of Caldolor on <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> was evaluated in two multi-center, randomized, double-blind, placebo-controlled studies.
</p>
<p> In a study of women who had undergone an elective abdominal hysterectomy, 319 patients were randomized and treated with Caldolor 800 mg or placebo administered every 6 hours (started intra-operatively) and morphine administered on an as needed basis.  Efficacy was demonstrated as a statistically significant greater reduction in the mean morphine consumption through 24 hours in patients who received Caldolor as compared to those receiving placebo (47 mg and 56 mg, respectively).  The clinical relevance of this finding is supported by a greater reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity over 24 hours for patients treated with Caldolor, even though morphine was available on an as needed basis.
</p>
<p> In a study of patients who had undergone an elective abdominal or orthopedic surgery, 406 patients (87 men, 319 women) were randomized to receive Caldolor 400 mg, Caldolor 800 mg, or placebo administered every 6 hours (started intra-operatively), and morphine on an as needed basis.   This study failed to demonstrate a statistically significant difference in outcome between patients receiving Caldolor 800 mg or 400 mg and placebo, although there were trends favoring the active treatments.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-12.2"></a><p></p>
<h2>14.2  Antipyretic (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>)
</h2>
<p class="First"> The effect of Caldolor on <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> was evaluated in two randomized, double-blind studies.
</p>
<p> In a multi-center study, 120 hospitalized patients (88 men, 32 women) with temperatures of 101°F or greater were randomized to Caldolor 400 mg, 200 mg, 100 mg or placebo, administered every 4 hours for 24 hours.  Each of the three Caldolor doses, 100 mg, 200 mg, and 400 mg, resulted in a statistically greater percentage of patients with a reduced temperature (&lt;101°F) after 4 hours, compared to placebo  (65%, 73%, 77%  and 32%, respectively).  The dose response is shown in the figure below.
</p>
<p><span class="Bold">Figure 1: Temperature Reduction by Treatment Group, Hospitalized Febrile Patients</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1eaa7790-f1a1-4f51-b10a-cbbaf033f684&amp;name=cal05-0000-02.jpg">
</div>
<p> In a single-center study, 60 hospitalized patients (48 men, 12 women) with uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> having temperatures
≥100.4°F were randomized to Caldolor 400 mg or placebo, administered every 6 hours for 72 hours of treatment.  There was a significant reduction in <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> within the first 24 hours of treatment, measured as the area above the temperature 98.6°F <span class="Italics">vs</span>. time curve for patients treated with Caldolor.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s57"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Caldolor is available in the following strengths:
</p>
<p><span class="Bold">800 mg/8 mL</span> (100 mg/mL)<br>        Carton of 25 vials, NDC 66220-287-08
</p>
<p>Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
</p>
<p>The stopper in the Caldolor vial does not contain natural rubber latex, dry natural rubber, or blends of natural rubber.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s58"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Patients should be informed of the following information before initiating therapy with an NSAID.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-14.1"></a><p></p>
<h2>17.1 Cardiovascular Effects
</h2>
<p class="First">Ibuprofen, like other NSAIDs, may cause serious CV events such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, advise patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and slurring of speech, and to ask for medical advice when observing any indicative sign or symptoms. Inform patients of the importance of this follow-up <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-14.2"></a><p></p>
<h2>17.2 Gastrointestinal Effects
</h2>
<p class="First">Ibuprofen, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, advise patients to be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and to ask for medical advice when observing any indicative signs or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Inform patients of the importance of this follow-up <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-14.3"></a><p></p>
<h2>17.3 Hepatotoxicity
</h2>
<p class="First"> Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and “flulike? symptoms). Instruct patients to stop therapy with Caldolor and seek immediate medical therapy if any of these occur <span class="Italics">[see Warnings and Precautions (</span><span class="Italics Underline"><a href="#s17">5.3</a></span><span class="Italics">)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-14.4"></a><p></p>
<h2>17.4 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>
</h2>
<p class="First">Ibuprofen, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS and TEN, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, advise patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and to ask for medical advice when observing any indicative sign or symptoms. Advise patients to stop Caldolor immediately if they  develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and to contact a physician as soon as possible <span class="Italics">[see Warnings and Precautions (<a href="#s22">5.8</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-14.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</h2>
<p class="First"> Advise patients to promptly report to their physicians signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> during treatment with Caldolor <span class="Italics">[see Warnings and Precautions (</span><span class="Italics Underline"><a href="#s19">5.5</a></span><span class="Italics">)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-14.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</h2>
<p class="First">Inform patients of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g. difficulty in breathing, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, therapy should be discontinued and medical therapy initiated <span class="Italics">[see Warnings and Precautions (<a href="#s21">5.7</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-14.7"></a><p></p>
<h2>17.7 Effects During Pregnancy
</h2>
<p class="First">Starting at 30 weeks gestation, Caldolor and other NSAIDs should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur <span class="Italics">[see Use in Specific Populations (</span><span class="Italics Underline"><a href="#s43">8.1</a></span><span class="Italics">)].</span></p>
<p>Manufactured for:<br>Cumberland Pharmaceuticals Inc.<br>Nashville, TN 37203<br>US Patent Number 6,727,286
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s66"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 8 mL Vial Label</span></p>
<p>NDC 66220-287-08 <span class="Bold">Rx Only</span></p>
<p><span class="Bold">Caldolor<span class="Sup">®</span><br>(ibuprofen) Injection</span></p>
<p><span class="Bold">800 mg/8 mL</span></p>
<p>(100 mg/mL)
</p>
<p><span class="Bold">FOR INTRAVENOUS USE. MUST DILUTE BEFORE USE.</span></p>
<p><span class="Bold">Store at controlled room temperature,<br>20°C - 25°C (68° - 77°F).</span></p>
<p>Single dose vial, discard unused portion.
</p>
<p><span class="Bold">DOSAGE:</span> See package insert for dosage,<br>dilution, and administration information.
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel - 8 mL Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1eaa7790-f1a1-4f51-b10a-cbbaf033f684&amp;name=cal05-0000-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s67"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 8 mL Carton Label</span></p>
<p>NDC 66220-287-08
</p>
<p>25 x 8 mL Vials
</p>
<p><span class="Bold">800 mg/8 mL</span></p>
<p><span class="Bold">For Intravenous Use</span></p>
<p><span class="Bold">Must Dilute Before Use</span></p>
<p><span class="Bold">Caldolor<span class="Sup">®</span><br>(ibuprofen) Injection</span></p>
<p><span class="Bold">800 mg/8 mL</span></p>
<p>(100 mg/mL)
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel - 8 mL Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1eaa7790-f1a1-4f51-b10a-cbbaf033f684&amp;name=cal05-0000-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CALDOLOR 		
					</strong><br><span class="contentTableReg">ibuprofen injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66220-247</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ibuprofen</strong> (ibuprofen) </td>
<td class="formItem">ibuprofen</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>arginine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66220-247-04</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022348</td>
<td class="formItem">06/11/2009</td>
<td class="formItem">12/01/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CALDOLOR 		
					</strong><br><span class="contentTableReg">ibuprofen injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66220-287</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ibuprofen</strong> (ibuprofen) </td>
<td class="formItem">ibuprofen</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>arginine</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66220-287-08</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">8 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022348</td>
<td class="formItem">06/11/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cumberland Pharmaceuticals Inc.
							(069532880)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a8e3ca83-b736-4ec6-868b-48f5e40ad3c5</div>
<div>Set id: 1eaa7790-f1a1-4f51-b10a-cbbaf033f684</div>
<div>Version: 2</div>
<div>Effective Time: 20140328</div>
</div>
</div> <div class="DistributorName">Cumberland Pharmaceuticals Inc.</div></p>
</body></html>
